Axitinib Ups Neuroendocrine Tumor Objective Response Rate
TOPLINE: Axitinib combined with octreotide long-acting release (LAR) significantly improved progression-free survival (PFS) per blinded independent central review (BICR) and objective response rate in patients with advanced extrapancreatic neuroendocrine …